Profil
René Vleugels was the founder of AdjuTec BV (2017), MUbio Holding BV (2000), and CyTuVax BV (2011) where he held the titles of Managing Director and Chief Executive Officer respectively.
Dr. Vleugels is also the founder of NovoVacs BV.
He worked as a Principal at Maastricht University and earned a doctorate degree from Radboud University Nijmegen in 1990.
Postes actifs de René Vleugels
| Sociétés | Poste | Début |
|---|---|---|
| NovoVacs BV | Fondateur | 01/09/2009 |
CyTuVax BV
 CyTuVax BV Pharmaceuticals: MajorHealth Technology CyTuVax BV develops vaccinations for cancer treatment. Its vaccination technology includes an adjuvant composed of depot-bound cytokines acting as immune response modifiers. The firm also provides adjuvant technology licensing services. The company was founded by René Vleugels and Frank W. Falkenberg in 2011 and is headquartered in Maastricht, the Netherlands. | Directeur Général | 01/01/2011 |
Anciens postes connus de René Vleugels
| Sociétés | Poste | Fin |
|---|---|---|
| Maastricht University | Corporate Officer/Principal | - |
AdjuTec BV
 AdjuTec BV Pharmaceuticals: MajorHealth Technology AdjuTec BV is a Dutch company that manufactures personalized therapeutic tumor vaccines for pancreatic and liver cancer patients. The company is based in Maastricht, Netherlands. The company was founded in 2017 by René Vleugels. | Fondateur | - |
MUbio Holding BV
 MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Fondateur | - |
Formation de René Vleugels
| Radboud University Nijmegen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
MUbio Holding BV
MUbio Holding BV BiotechnologyHealth Technology MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine. | Health Technology |
| NovoVacs BV | |
CyTuVax BV
CyTuVax BV Pharmaceuticals: MajorHealth Technology CyTuVax BV develops vaccinations for cancer treatment. Its vaccination technology includes an adjuvant composed of depot-bound cytokines acting as immune response modifiers. The firm also provides adjuvant technology licensing services. The company was founded by René Vleugels and Frank W. Falkenberg in 2011 and is headquartered in Maastricht, the Netherlands. | Health Technology |
AdjuTec BV
AdjuTec BV Pharmaceuticals: MajorHealth Technology AdjuTec BV is a Dutch company that manufactures personalized therapeutic tumor vaccines for pancreatic and liver cancer patients. The company is based in Maastricht, Netherlands. The company was founded in 2017 by René Vleugels. | Health Technology |